Jiangsu Hengrui Pharmaceuticals revenue and financials
¥47.20Change from previous close: +3.46%Absolute change: +¥1.58
In the fiscal year ended December 2025, Jiangsu Hengrui Pharmaceuticals reported revenue of ¥31.63B (+13.02% year over year). Net income was ¥7.71B, a net margin of 24.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +13.02%
- 2025 vs 2024
- Net income growth
- +21.69%
- 2025 vs 2024
- Net margin
- 24.4%
- 2024: 22.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total revenue | 7,315 | 8,141 | 8,441 | 8,556 | 7,206 |
| Cost of revenue | 1,022 | 1,091 | 1,167 | 1,046 | 1,069 |
| Gross profit | 6,293 | 7,050 | 7,274 | 7,509 | 6,137 |
| Selling, general and administrative | 400 | 2,814 | -1,549 | 1,104 | 2,553 |
| Research and development | 1,842 | 1,651 | 2,016 | 1,695 | 1,533 |
| Operating income | 1,671 | 2,580 | 2,330 | 2,808 | 2,018 |
| EBIT | 2,398 | 2,557 | 2,298 | 2,976 | 2,087 |
| EBITDA | 2,398 | 2,557 | 2,298 | 2,976 | 2,087 |
| Interest expense | 2.6 | 0.4 | 2.0 | 0.7 | 10.9 |
| Pre-tax income | 2,396 | 2,557 | 2,296 | 2,975 | 2,076 |
| Income tax | 211 | 276 | 339 | 397 | 199 |
| Net income | 2,183 | 2,282 | 1,960 | 2,576 | 1,874 |
| Net income to common shareholders | 2,183 | 2,282 | 1,960 | 2,576 | 1,874 |
| Basic EPS | — | 0.34 | — | — | 0.30 |
| Diluted EPS | — | 0.34 | — | — | 0.30 |
| Average shares (basic) | — | 6,713 | — | — | 6,247 |
| Average shares (diluted) | — | 6,713 | — | — | 6,247 |